Obermatt
See Similar Stocks →

Metagenomi Therapeutics

NSQ:MGX · US59102M1045
BiotechnologySmall

360

24
Profit price16
Owner Earnings Yield1
Dividend Yield1
Price/Sales84
Price/Book73
Return on Capital60
Cash Return on Capital55
Return on Equity73
Profit margins22
Accruals68
Owner Earnings Margin38
Sales growth10
Profit growth79
Reinvestment54
Price momentum16
Debt load27
Refinancing3
Debt Payback1
Liquidity64
Analyst ratings24
Expectations trend6
Market mood14
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Metagenomi Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2016
Employees142
Websitemetagenomi.co
ISINUS59102M1045
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
HematologyGeneticsCentral Nervous SystemGenetic DisorderOncology

Description

Metagenomi Therapeutics, Inc. operates as a precision genetic medicines company. The company is developing curative therapeutics for patients using its proprietary, genome editing toolbox. The company is harnessing the power of metagenomics, the st…

Analysis

Middle-of-the-road

Metagenomi Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
4
2026

All-time high

8

Mar 2026

All-time low

4

Jun 2026

Average rank

6

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
84
—
—
—
Price/Earnings
11
—
—
—
Price/Book
73
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
37
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Metagenomi Therapeutics with its peers
Prelude Therapeutics
NSQ:PRLD
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Beam Therapeutics
NSQ:BEAM
17
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sionna Therapeutics
NMQ:SION
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Relay Therapeutics
NMQ:RLAY
23
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Seres Therapeutics
NSQ:MCRB
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Apogee Therapeutics
NMQ:APGE
58
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →